Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 8,580 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ocugen Inc | OCGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -3.03% | 1.28 | 06:49:07 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.32 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 61 | 8,580 | - | 0.345 - 2.105 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:00:00 | formt | 700 | $ 1.28 | USD |
Ocugen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 338.58M | 256.50M | - | 0 | -81.35M | -0.32 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ocugen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.69 | 1.76 | 1.27 | 1.52 | 6,631,402 | -0.41 | -24.26% |
| 1 Month | 1.45 | 2.105 | 1.27 | 1.69 | 13,481,605 | -0.17 | -11.72% |
| 3 Months | 0.58 | 2.105 | 0.495 | 1.31 | 9,422,491 | 0.70 | 120.69% |
| 6 Months | 0.417 | 2.105 | 0.345 | 1.12 | 5,720,520 | 0.863 | 206.95% |
| 1 Year | 0.8501 | 2.105 | 0.345 | 0.844588 | 5,515,147 | 0.4299 | 50.57% |
| 3 Years | 5.40 | 17.65 | 0.345 | 6.83 | 14,219,751 | -4.12 | -76.30% |
| 5 Years | 3.24 | 18.77 | 0.17 | 5.45 | 17,822,669 | -1.96 | -60.49% |
Ocugen Description
| Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. |
